


AMENDMENTS TO THE CLAIMS

Claims 1 and 13-21 have been amended without any intention of disclaiming equivalents thereof. Claim 12 has been canceled without prejudice to its subsequent reintroduction into this application or its introduction into a related application. New claims 22-24 have been added. This listing of claims will replace all prior versions, and lists, of the claims in the application.

What is Claimed is:

1. (Currently Amended) A ~~composition comprising~~ a drug-eluting stent media coated on a vascular stent; wherein said drug-eluting stent media comprises a benzodiazepine compound in an amount effective to inhibit restenosis in a subject, ~~pharmaceutical composition designed to bind a mitochondrial oligomycin sensitivity conferring protein component in a mammalian subject~~; wherein said ~~pharmaceutical composition~~ comprises an agent capable of binding a mitochondrial oligomycin sensitivity conferring protein component, wherein said agent ~~does not bind to a central benzodiazepine receptor and binds only with low affinity to a peripheral benzodiazepine receptor~~, wherein said agent wherein the benzodiazepine compound is:



2-12. (Canceled)

13. (Currently Amended) The drug-eluting stent media ~~composition~~ of Claim 1 ~~12~~, wherein said ~~drug-eluting~~ stent is seeded with endothelial cells.

14. (Currently Amended) The drug-eluting stent media ~~composition~~ of Claim 1, ~~wherein said drug-eluting stent media~~ further ~~comprises~~ comprising an anticoagulant drug.

15. (Currently Amended) The drug-eluting stent media ~~composition~~ of Claim 1, ~~wherein said drug-eluting stent media~~ further ~~comprises~~ comprising an antiplatelet drug.
16. (Currently Amended) The drug-eluting stent media ~~composition~~ of Claim 1, ~~wherein said drug-eluting stent media~~ further ~~comprises~~ comprising an antimicrobial agent.
17. (Currently Amended) The drug-eluting stent media ~~composition~~ of Claim 1, ~~wherein said drug-eluting stent media~~ further ~~comprises~~ comprising an anti-inflammatory agent.
18. (Currently Amended) The drug-eluting stent media ~~composition~~ of Claim 1, ~~wherein said drug-eluting stent media~~ further ~~comprises~~ comprising an anti-metabolic agent.
19. (Currently Amended) The drug-eluting stent media ~~composition~~ of Claim 1, ~~wherein said drug-eluting stent media~~ further ~~comprises~~ comprising a vasoreactive agent.
20. (Currently Amended) The drug-eluting stent media ~~composition~~ of Claim ~~19~~ 44, wherein said vasoreactive agent is a nitric oxide releasing agent.
21. (Currently Amended) The drug-eluting stent media ~~composition~~ of Claim 1, wherein said subject is a human being.
22. (New) The drug-eluting stent media of Claim 1, wherein the drug-eluting stent media, when placed in a subject, releases the benzodiazepine such that cells in the subject are exposed to the benzodiazepine at a concentration of less than 10 μ M.
23. (New) The drug-eluting stent media of Claim 1, wherein the benzodiazepine compound is the only therapeutic agent in the drug eluting stent media.
24. (New) The drug-eluting stent media of Claim 22, wherein the benzodiazepine compound is the only therapeutic agent in the drug eluting stent media.